Evidence map›Paper›PMID 37577511›Full record

ArticlemedRxiv : the preprint server for health sciences2023

A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis.

Chandrasekaran Padmapriyadarsini, John D Szumowski, Nabila Akbar, Prema Shanmugasundaram, Anilkumar Jain, Marasamy Bathragiri, Manoranjan Pattnaik, Jyotirmayee Turuk, Ramesh Karunaianantham, Senthilkumar Balakrishnan and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 3 countries.

Chandrasekaran PadmapriyadarsiniNational Institute for Research in Tuberculosis, Chennai, India.
John D SzumowskiDivision of HIV, Infectious Diseases and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, USA.
Nabila AkbarNational Institute for Research in Tuberculosis, Chennai, India.
Prema ShanmugasundaramNational Institute for Research in Tuberculosis, Chennai, India.
Anilkumar JainNational Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
Marasamy BathragiriGovernment Kilpauk Medical College and Hospital, Chennai, India.
Manoranjan PattnaikDepartment of Pulmonary Medicine, SCB Medical College, Cuttack, India.
Jyotirmayee TurukRegional Medical Research Centre, Bhubaneswar, India.
Ramesh KarunaiananthamNational Institute for Research in Tuberculosis, Chennai, India.
Senthilkumar BalakrishnanNational Institute for Research in Tuberculosis, Chennai, India.
Sangamitra PatiRegional Medical Research Centre, Bhubaneswar, India.
Hemanth K Agibothu KupparamNational Institute for Research in Tuberculosis, Chennai, India.
Manoj Kumar RathoreSITEC Labs, Navi Mumbai, India.
Jegadeesh RajaSITEC Labs, Navi Mumbai, India.
K Raghu NaiduSITEC Labs, Navi Mumbai, India.
John HornDepartment of Pharmacy, University of Washington, Seattle, USA.
Laura WhitworthMolecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge UK.
Roger SewellTrinity College, Cambridge, UK.
Lalita RamakrishnanMolecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge UK.
Soumya SwaminathanNational Institute for Research in Tuberculosis, Chennai, India.
Paul H EdelsteinMRC Laboratory of Molecular Biology, Cambridge, UK.
National Institute of Research in Tuberculosis · INMRC Laboratory of Molecular Biology · GBRegional Medical Research Centre · INGovernment Kilpauk Medical College · INLRS Institute of Tuberculosis and Respiratory Diseases · INSan Francisco General Hospital · USSriram Chandra Bhanja Medical College Hospital · INTrinity College London · GBUniversity of Washington · US

Funding

HOST DEFENSE TRAINING IN ALLERGY AND INFECTIOUS DISEASEST32AI007044 · NIAID · UNIVERSITY OF WASHINGTON · PI DAVID Neal FREDRICKS · 1985 to 2026
$14.6M
Host Responses to Mycobacterium Infection in ZebrafishR01AI054503 · NIAID · UNIVERSITY OF WASHINGTON · PI LALITA RAMAKRISHNAN · 2003 to 2026
$4.4M
NIAID NIH HHS T32 AI007044Wellcome Trust
6 · The paper itself

Abstract

Induction of mycobacterial efflux pumps is a cause of

Indexed as

drug toleranceeffluxnorverapamilrifampinR-verapamiltuberculosisverapamil

Identifiers

PMID37577511
PMCPMC10418293
OpenAlexW4385605200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.